Kyrsten Sinema pledges support for Ibogaine research, a drug used to treat brain disorders
The Brief
Former U.S. Senator Kyrsten Sinema advocated in favor of funding research for a drug to treat brain disorders at the Arizona State Capitol.
House Bill 28-71 seeks funding for Ibogaine, a naturally occurring plant that grows in Africa.
Ibogaine has been used by military veterans but has potentially dangerous side effects, requiring more research.
PHOENIX - Former Arizona Senator Kyrsten Sinema returned to the Arizona State Capitol on Monday to advocate for a bill that would fund research for a psychedelic drug to treat brain disorders.
House Bill 28-71 would authorize $5 million for clinical studies into the use of Ibogaine.
What we know
"There is no major pharmacuitical company to bankroll this effort and then make billions on the back end," Sinema said.
The drug comes from a plant in West Africa and has been used in other countries to treat traumatic brain injuries, PTSD, other neurological disorders and addiction.
It has to be administered by a doctor and can have dangerous side effects.
"Ibogaine is currently listed as a Schedule 1 drug by the DEA, which means no one in the US can access this medicine," she added.
Why you should care
Sinema pledged to help raise $5 million in matching funds if the bill is approved by state politicians.
She was joined by two military veterans who went to northern Mexico for Ibogaine treatment.
"You are starring at someone who got a second chance at life because of that medicine," said one of the veterans.
"To me Ibogaine, what it gave me is white space to be able to build new systems in my brain to get healthy," said the other.
What's next
The Arizona House Appropriations Committee approved the bill on Monday, Feb. 24 and the bill now goes to the full house for consideration.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Axios
22-05-2025
- Axios
Texas lawmakers poised to ban THC, threatening massive hemp industry
The Texas Legislature is poised to approve a ban on THC. Why it matters: The move would spell trouble for Texas' multibillion-dollar hemp industry, leaving those who rely on legal over-the-counter THC products, including veterans, in the lurch. Driving the news: The Texas House on Wednesday took an initial vote in favor of Senate Bill 3, already passed by the Senate. A final House vote could come as soon as Thursday, potentially sending the bill back to the Senate to approve minor changes — and then likely to Gov. Greg Abbott's desk. Abbott, who can veto the effort, hasn't indicated his thoughts on the issue. When asked about his stance on the bill, his office told the Texas Tribune he "will thoughtfully review any legislation sent to his desk." Context: The fight is over consumable delta-8 THC, which Texas lawmakers legalized in 2019. Delta-8 THC is a minor chemical variant of the main psychoactive ingredient in traditional cannabis and provides lesser psychoactive effects. It can be coupled with CBD, another hemp-derived compound used for pain relief and mental wellness. In 2019, Abbott signed the Texas farm bill, which partly legalized products containing small amounts of hemp-derived delta-8 THC, including edibles, beverages, vapes and traditional bud. Yes, but: Lt. Gov. Dan Patrick in 2024 waged war on the substance, saying products were being sold with "unlimited THC" and marketed to children with "life-threatening" consequences. With Patrick's backing, state Sen. Charles Perry (R-Lubbock) filed the THC ban bill in February. The Senate passed it 26-5 in March. Friction point: The Legislature appeared torn on how to move forward with consumable hemp-derived THC. Republican state Rep. Ken King filed House Bill 28, competing legislation seeking to instead regulate legal THC by imposing age restrictions, banning synthetic cannabinoids and introducing strict licensing requirements for the hemp industry. That bill received a hearing in the House Committee on State Affairs on April 7, the same day the committee heard testimony on SB 3. While SB 3 was voted out of the committee in the following days, HB 28 languished. What they're saying:"Banning this entire category won't protect children, but it will have devastating economic impacts on Texas hemp farmers, retailers, distributors and more," Jake Bullock, CEO of THC beverage company Cann, sold across Texas, said in a statement. "Instead of imposing the sensible regulations companies like ours have been advocating for … lawmakers compounded the problem by driving dangerous untested high-dose synthetic products underground and by taking away adults' freedom to choose the safe products they want," Bullock said. The other side: Patrick said regulating THC isn't possible, calling the substance "poison" in a social media video he shared this week. "We can't regulate it," Patrick said. "We don't have enough police to check every store when there are 8,000 to 9,000 of them." The big picture: The move comes as more states have loosened cannabis restrictions in recent years. Twenty-four states and the District of Columbia allow the sale of marijuana for recreational purposes, and medical marijuana is legal in 39 states, including a limited program in Texas, and the district, per Stateline.
Associated Press
22-05-2025
- Associated Press
Ibogaine By David Dardashti to Share Groundbreaking Ibogaine Treatment Protocol Insights, Including for Neurodegenerative Conditions and Diabetes, at Psychedelic Science 2025 in Denver
DENVER, CO - May 21, 2025 - Ibogaine By David Dardashti, will be hosting a booth at the upcoming Psychedelic Science 2025 conference, hosted by the Multidisciplinary Association for Psychedelic Studies (MAPS). The conference, a premier global gathering for psychedelic research, medicine, policy, and culture, will take place from June 16-20, 2025, at the Colorado Convention Center. Ibogaine By David Dardashti is expected to share profound insights into specific ibogaine treatment protocols tailored to diverse needs, a hallmark of his approach. This information will delve into the nuanced application of ibogaine for a range of conditions, including: Attendees will gain a precise understanding of the ramifications of these specific treatment lengths in relation to an individual's unique needs and circumstances. Dardashti will also illuminate the overall ibogaine experience, explaining its mechanisms and transformative potential with clarity and precision, particularly concerning its application beyond addiction to other challenging health conditions. Known for his work at Ibogaine by David Dardashti, he has long advocated for individualized care, emphasizing the importance of addressing the root causes of various ailments. His presence at Psychedelic Science 2025 offers a significant opportunity for clinicians, researchers, and the wider psychedelic community to learn about these structured and potentially pioneering approaches to ibogaine therapy. About David Dardashti: David Dardashti is a leading expert in ibogaine treatment with extensive experience in developing personalized protocols for addiction, psychological well-being, and other complex health conditions. About Psychedelic Science 2025: Psychedelic Science 2025, hosted by MAPS, is the leading international conference dedicated to the study of psychedelic substances for science, medicine, spirituality, and policy. It brings together experts from around the world to share the latest research and developments in the field. Media Contact Company Name: Ibogaine By David Dardashti Contact Person: Cole Barressi Email: Send Email Country: United States Website: Press Release Distributed by To view the original version on ABNewswire visit: Ibogaine By David Dardashti to Share Groundbreaking Ibogaine Treatment Protocol Insights, Including for Neurodegenerative Conditions and Diabetes, at Psychedelic Science 2025 in Denver
Washington Post
17-05-2025
- Washington Post
Now its Senate Republicans who want to undermine the filibuster
With the possible exception of springtime pollen, there are few things more predictable in Washington than the opportunism with which Democrats and Republicans switch sides on the question of the Senate filibuster. Back when Joe Biden was president and Democrats held the narrowest of Senate majorities, only two of their caucus members — Democrats-turned-independents Joe Manchin III of West Virginia and Kyrsten Sinema of Arizona — stood against their party's effort to end the dilatory tactic on some issues. Filibuster rules create a situation in which most legislation requires 60 votes to pass.
